$heff's $tation of $tocks & $olid DD

[$heff]

ZGNX..alert bought at $2.33..DD POST Attached. The company has two upcoming catalysts. They are expecting an ADCOM panel meeting in Nov/Dec 2012. They also have a PDUFA date for March 1st . The 52wk high is $3.23 & 52wk low is $1.31. The company has 100m shares outstanding & 75m shares in the float. 44% insider holding and 31% institutional holdings. The market cap at $2.33 is 233M.
The company raised cash through dilution & payed off their debt. http://stks.co/i9Xe. DISCLAIMER & INFORMATION FOR READERS: http://bit.ly/OlN9DB


Shares Outstanding via 10Q


Zogenix CEO Discusses Q2 2012 Results
http://bit.ly/OFyjWf

FORM SC 13G-Institutional Buying on 8/3/12 by Great Point Partners, LLC 5.8m shares at 5.8% ownership
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=8751311

FORM SC 13G-Institutional Buying on 8/10/12 by Federated Investors Inc. 30.45m shares at 28.37%
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=8764735

FDA Acceptance for review of Zohydro ER. PDUFA on March 1st
http://bit.ly/Pb8FKi

July 2012 Offering. Prices 32.5m units at $2/Unit. Gross proceeds are 65.5m.
http://bit.ly/OeUIbm Zogenix intends to use the net proceeds from the offering to repay all amounts outstanding under its amended and restated loan and security agreement with Oxford Finance LLC and Silicon Valley Bank, to fund the pre-approval and pre-commercialization activities of Zohydro™ ER, for the ongoing commercialization of Sumavel® DosePro® and for working capital and other general corporate purposes.

Stifel Nicolaus reduces PT to $6 on share offering.
http://bit.ly/SaeLsx

KEY CATALYST IN Q4 2012 is FDA ADCOM Mtng. PDUFA is March 1st, 2013
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=8762429



KEY STATISTICS

Historical Prices




Product Slides




DISCLAIMER & INFORMATION FOR READERS: http://bit.ly/OlN9DB